Patents by Inventor Erika Pfeiler

Erika Pfeiler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Lactobacillus with decreased lipoteichoic acid to reduce inflammatory responses
    Patent number: 9980992
    Abstract: Methods and compositions for treating or preventing inflammatory disorders are provided. The compositions of the invention comprise a recombinant bacterium genetically modified to decrease the display of lipoteichoic acid on the cell surface. Methods of the invention comprise administering to a subject a recombinant bacterium modified to decrease the display of lipoteichoic acid on the cell surface. Administration of the recombinant bacterium promotes a desired therapeutic response. The recombinant bacterium may be administered in a single dose or series of doses. Methods of the invention find use in treating or preventing a variety of inflammatory disorders including, for example, treating or preventing inflammatory bowel disease, colitis, or Crohn's disease.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: May 29, 2018
    Assignees: Northwestern University, North Carolina State University
    Inventors: Todd R. Klaenhammer, Erika Pfeiler, Mansour Mohamadzadeh
  • RECOMBINANT LACTOBACILLUS WITH DECREASED LIPOTEICHOIC ACID TO REDUCE INFLAMMATORY RESPONSES
    Publication number: 20160324905
    Abstract: Methods and compositions for treating or preventing inflammatory disorders are provided. The compositions of the invention comprise a recombinant bacterium genetically modified to decrease the display of lipoteichoic acid on the cell surface. Methods of the invention comprise administering to a subject a recombinant bacterium modified to decrease the display of lipoteichoic acid on the cell surface. Administration of the recombinant bacterium promotes a desired therapeutic response. The recombinant bacterium may be administered in a single dose or series of doses. Methods of the invention find use in treating or preventing a variety of inflammatory disorders including, for example, treating or preventing inflammatory bowel disease, colitis, or Crohn's disease.
    Type: Application
    Filed: April 13, 2016
    Publication date: November 10, 2016
    Applicants: North Carolina State University, Northwestern University
    Inventors: Todd R. Klaenhammer, Erika Pfeiler, Mansour Mohamadzadeh
  • Recombinant Lactobacillus with decreased lipoteichoic acid to reduce inflammatory responses
    Patent number: 9340792
    Abstract: Methods and compositions for treating or preventing inflammatory disorders are provided. The compositions of the invention comprise a recombinant bacterium genetically modified to decrease the display of lipoteichoic acid on the cell surface. Methods of the invention comprise administering to a subject a recombinant bacterium modified to decrease the display of lipoteichoic acid on the cell surface. Administration of the recombinant bacterium promotes a desired therapeutic response. The recombinant bacterium may be administered in a single dose or series of doses. Methods of the invention find use in treating or preventing a variety of inflammatory disorders including, for example, treating or preventing inflammatory bowel disease, colitis, or Crohn's disease.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: May 17, 2016
    Assignees: North Carolina State University, Northwestern University
    Inventors: Todd R. Klaenhammer, Erika Pfeiler, Mansour Mohamadzadeh
  • RECOMBINANT LACTOBACILLUS WITH DECREASED LIPOTEICHOIC ACID TO REDUCE INFLAMMATORY RESPONSES
    Publication number: 20130224153
    Abstract: Methods and compositions for treating or preventing inflammatory disorders are provided. The compositions of the invention comprise a recombinant bacterium genetically modified to decrease the display of lipoteichoic acid on the cell surface. Methods of the invention comprise administering to a subject a recombinant bacterium modified to decrease the display of lipoteichoic acid on the cell surface. Administration of the recombinant bacterium promotes a desired therapeutic response. The recombinant bacterium may be administered in a single dose or series of doses. Methods of the invention find use in treating or preventing a variety of inflammatory disorders including, for example, treating or preventing inflammatory bowel disease, colitis, or Crohn's disease.
    Type: Application
    Filed: June 16, 2011
    Publication date: August 29, 2013
    Applicants: NORTHWESTERN UNIVERSITY, NORTH CAROLINA STATE UNIVERSITY
    Inventors: Todd R. Klaenhammer, Erika Pfeiler, Mansour Mohamadzadeh